This month, we profile Magazine – Dr. Michael Tolentino, a leading force in ophthalmology and a serial biotech entrepreneur.  Dr. Tolentino’s fingerprints are on some of the most impactful treatments for retinal diseases, including Avastin and gene therapy research.  But his true passion lies in revolutionizing how we treat illness.

Aviceda Therapeutics, his latest venture, tackles disease at its root by “reprogramming” the immune system.  Their approach utilizes sugar codes to modulate immune cells, offering a potentially safer and more effective approach to a wide range of conditions.  Early results in geographic atrophy, a blinding form of macular degeneration, are particularly promising.

Dr. Tolentino’s relentless pursuit of cures extends beyond the eye.  His sights are set on tackling diseases like cancer, Alzheimer’s, and allergies.  With a proven track record and a revolutionary platform, Dr. Tolentino is poised to reshape the future of healthcare.Magazine – Dr. Michael Tolentino

This month, we profile Magazine – Dr. Michael Tolentino, a leading force in ophthalmology and a serial biotech entrepreneur.  Dr. Tolentino’s fingerprints are on some of the most impactful treatments for retinal diseases, including Avastin and gene therapy research.  But his true passion lies in revolutionizing how we treat illness.

Aviceda Therapeutics, his latest venture, tackles disease at its root by “reprogramming” the immune system.  Their approach utilizes sugar codes to modulate immune cells, offering a potentially safer and more effective approach to a wide range of conditions.  Early results in geographic atrophy, a blinding form of macular degeneration, are particularly promising.

Dr. Tolentino’s relentless pursuit of cures extends beyond the eye.  His sights are set on tackling diseases like cancer, Alzheimer’s, and allergies.  With a proven track record and a revolutionary platform, Dr. Tolentino is poised to reshape the future of healthcare.Magazine – Dr. Michael Tolentino